NCT00355238 2023-12-01
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
15 trialsNCT00908752 2019-12-02
BRISK TA
Bristol-Myers Squibb
Phase 3 Completed
NCT00825955 2019-10-09
BRISK PS
Bristol-Myers Squibb
Phase 3 Completed
NCT03516071 2019-09-04
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT00594984 2015-11-04
Phase I/II Combination With Irinotecan- Erbitux
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00633789 2015-10-09
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Bristol-Myers Squibb
Phase 2 Completed
NCT00798252 2015-07-07
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Bristol-Myers Squibb
Phase 1 Completed
NCT01046864 2014-09-16
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
Bristol-Myers Squibb
Phase 1 Completed
NCT01540461 2014-07-08
Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
Bristol-Myers Squibb
Phase 1 Completed
NCT00437437 2013-06-21
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
Bristol-Myers Squibb
Phase 1 Completed
NCT00437424 2011-05-04
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
Bristol-Myers Squibb
Phase 1 Completed
NCT00207051 2011-01-25
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
Bristol-Myers Squibb
Phase 1 Completed
NCT00390936 2011-01-25
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT00435669 2009-01-22
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
Bristol-Myers Squibb
Phase 1 Completed
NCT00207103 2008-11-04
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed